Basket | Login | Register


Genentech completes recruitment of participants for second Phase 3 trial of AD drug crenezumab

Tuesday 17 July 2018

On 17 July, the Swiss-based biopharmaceutical company AC Immune announced that its partner Genentech, a member of the Roche group, has completed global recruitment of its Phase III CREAD 2 clinical trial of crenezumab. The study is investigating the drug crenezumab, which is a monoclonal antibody that specifically recognises amyloid beta (Aβ).

The CREAD2 Phase III trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of crenezumab in people with prodromal to mild Alzheimer's disease (AD). CREAD2 started in the first quarter of 2017 and completed global recruitment in July 2018.

"We are very happy that the CREAD 2 recruitment has been completed ahead of schedule. This clearly shows the strong commitment of our partner Roche/Genentech to the development of crenezumab as a potential disease-modifying therapy for Alzheimer's disease - one of society's biggest healthcare challenges", said Prof. Andrea Pfeifer, CEO of AC Immune.